Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine

European Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2001, Pages 377-386

  Sherwin, K B ^a   Tang, Bing Kou ^a   Tang, B K ^b   Kalow, W ^b  

^a DUPONT COMPANY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP1A1; CYP1A2; Differential inhibition; EROD; Fluvoxamine

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; ENZYME INHIBITOR; FLUVOXAMINE; ISOENZYME; PHENACETIN;

AGING; ARTICLE; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYME SPECIFICITY; ENZYMOLOGY; HUMAN; KINETICS; LIVER MICROSOME; METABOLISM; MOLECULAR PROBE; STATISTICAL MODEL;

AGING; CAFFEINE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MODELS, STATISTICAL; MOLECULAR PROBES; PHENACETIN; SUBSTRATE SPECIFICITY;

EID: 0035431276     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s0022S0100330     Document Type: Article

References (59)

1. Berthou F. Flinois J. Ratanasavanh D. Beaune P. Riche C, Guillouzo A (1991) Evidence for the involvement of several cytochromes P450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 19:561-567
2. Burke MD. Thompson S. Weaver RJ. Wolf CR, Mayer RT (1994) Cytochrome P45Ü specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923-936
3. Butler MA. Lane NP. Younc JF. Caporaso NE. Vincis P, Hayes RB, Teitel CH. Massengill JP. Lawsen MF, Kadlubar FF (1992) Determination of CYPIA2 and NAT2 phenotypes in human population by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127
4. Crespi CE. Penman BW, Steimel DT. Smith T. Yang CS, Sutler TR (1997) Development of a human lymphoblastoid cell line constitutive!) expressing human CYP1BI cDNA: substrate specificity with model substrates and promutasens. Mutagenesis 12:83-89
5. Drahushuk AT. McGarrigle BP. Larsen KE, Stegeman JJ. Olson JR (1998) Detection of C'YPIAI protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture. C'arcinogenesis 19:1361-1368
6. Drakoulis N. Cascorbi I. Brockmolfer J. Gross CR. Roots I (1994) DNA adducts profiles and levels in placenta, blood and lung in relation to ciuarette smokinti and smoky coal emissions. In: IARC Scientific Publication No. 124. IARC. Lyon, pp 283-292
7. Esteller M. Garcia A. Martinez-Palones JM, Xervcavins J. Revents .1 (1997) Susceptibility to endometrial cancer: influence of allelism at p53 glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 75:1385-1388
8. Farin FM. Omiecinski CJ (1993) Regiospecific expression of cytochrome P450s and microsomal epoxide hydrolase in human brain tissue. .1 Toxicol Environ Health 27:98-101
9. Forrester EM. Henderson C.I. Glancey MJ. Back DJ. Park BK. Ball SE. Kiltcringhain NR, McLaren AW. Miles JS. Skett P. Wolf C'R (1992) Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281:359-368
10. Goto I. Yoneda S, Yamamoto M. Kawajiri K (1996) Prognostic significance of germ line polymorphisms of the CYPIAI and glutathione S-transferase genes in patients with non-small cell hing cancer. Cancer Res 56:3725 3730
11. Gu L. Gonzales FJ. Kalow W. Tang B-K. (1992) Biotransformation of caffeine, paraxanthine. theobrominc and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2:73-77
12. Hakkola J. Pasanen M. Purkenen R. Saarikoski S. Pelkonen O. Maenpaa .1. Rane A. Raunio H (1994) Expression of xenobiotic-mclabolizing cytochrome P450 in human adult and fetal liver. Biochem Pharmacol 48:59 64
13. Hayashi S. Watanabe J. Kwajiri K (1992) High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase eenes. Jpn .1 Cancer Res 83:866 870 "
14. Hivonen A. Husgafvel-Pursiainen K. Karjalainen A. Anttila S, Vainio H (1992) Point-mutational MspI and Ile/Val polymorphisms closely linked in ihe CYPIAI gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1:485-489
15. Ioannides C. Parke DV (1990) The cytochrome P450 1A gene family of microsomal hemoproteins and their role in the metabolic activation of chemicals. Drug Metab Rev 22:1-85
16. Ishibe N. Wiencke JK. Zuo ZF. McMillan A. Spitz M. Kelsey KT (1997) Susceptibility to lung cancer in light smokers associated \\ith CYPIAI polymorphisms in Mexican- and AfricanAmericans. Cancer Epidemiol Biomarkers Prev 6:1075-1080
17. Kawajiri K. Nakachi K. Imai K. Yoshii A. Shinoda N. Watanabe.I (1990) Identification of geneticall) high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Eett 263:131-133
18. Kihara M. Kihara M. Noda K (1995) Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of C'YPIAI and GSTM I gene polymorphisms in a Japanese population. Carcinogencsis 16:2331-2336
19. Koser PE. Faletto MB. Moccubin AE. Gurtoo HE (1988) The genetics of aflatoxin Bl metabolism: association of the induction of aflatoxin B1-4-hydroxylase with the transcriptional activation of cytochrome P3 450 gene. J Biol Chem 263:12584-12595
20. Le Marchand L. Frank AA, Custer L. Wilkens LR. Cooney RV (1997) Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha tocopherol. Pharmacogenetics 7:116-127
21. Le Marchand L. Sivaraman L, Pierce L. Seifried A. Lum A. Wilkens LR, Lau AF ( 1998) Association of CYP l A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58:4858-4863
22. Lee QP, Fantel AG. Juchau MR (1991) Human embryonic cytochrome P45us: phenoxazone ethers as probes for expression of functional isotbrms during organosenesis. Biochem Pharmacol 42:2377-2385
23. Lin P. Wang S-L. Chen K-W. Lee H-S. Tsai K-J, Chen C-Y. Lee H (2000) Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. Br J Cancer 82:852-857
24. McKinnon RA, Hall PDLM, Quatlrochi LC. Tukcy RH. McManus ME (1991) Localization ofCYPlAl and CYP1A2 messenger RNA in normal human liver and hepalocellular carcinoma by in situ hybridization. Hepatology 14:848-856
25. Mooney LVA. Bell DA. Santella RM. van Bennekum AM. Ottman R, Paik M. Blauer WS. Lucier GW. Covey L. Young T-L. Cooper TB. Classman AH. Parera FP (1997) Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 18:503-509
26. Murray GI, Taylor MC McFadyen MCE. McKay JA. Greenlce WF. Burke D. Melvin WT (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57:3026-3031
27. Nakachi K. Imai K. Hayashi S, Kawajiri K (1993) Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53:2994-2999
28. Nakachi K. Hayashi S-L Kawajiri K, Imai K (1995) Association of cigarette smoking and CP1A1 polymorphisms with adenocarcinoma of the lung by izrades of differentiation. Carcinonenesis 16:2209-2213
29. Nakajima M, Yokoi T. Mizutani M. Shin S. Kadlubar FF. Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413-421
30. Okey AB. Riddick DS. Harper PA (1994) The Ah receptor: mediator of the toxicity of 2.3.7.8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol Lett 70:1-22
31. Omiecinski CJ. Redlich CA. Costa P (1990) Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction. Cancer Res 50:4315-4321
32. Ou-Yang DS, Huang SL. Wang W. Xie HG. Xu AH. Shu Y. Zhou HH (2000) Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 49:145-151
33. Pastrakuljic A, Tang BK, Roberts EA. Kalow W (1997) Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using tluvoxamine and isosafrole. Biochem Pharmacol 53:531-538
34. Penman BW. Chen L. Gelboin HV. Gonzalez FJ. Crespi, CL (1994) Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 cDNA: substrate specificity with model substrates and promutaaens. Carcinogenesis 15:1931-1937
35. Persson 1. Johansson I. Ingelman-Sundberg M (1997) In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 231:227-230
36. Quan T. Reiners JJ. Bell AO. Hong N. States JC (1994) Cylotoxicity and genotoxicity of ( ±)-benzo[a]pyrene-trans-7,8-dihydrodiol in CYP1A1 -expressing human fibroblast quantitatively correlate with CYP1A1 expression level. Carcinogenesis 15:1827-1832
37. Roberts EA. Xic ZW. Yang S. Lipa .1 ( 199?) Inducibiliu of enzyme activities associated will) the cytochrome P450 1A family, ethoxyrcsorufin O-deethylase. and melhoxyresorulin O-demethvlase in human hepatocvle lines derived from normal liver tissue. Drug Metah Dispos 21:56-61
38. Roberts-Thomson S.I. McManus ME:. Tukey RH. Gonzales FF. Holder GM (1993) The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen. Biochem Biophys Res Commun 192:1373-1379
39. Ryu D-Y. Levi PE. Fernandez-Salguero P. Gonzalez FJ. Hodgson E (1996) Piperonyl btitoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbonresponsive receptor knock-out mouse liver. Mol Pharmacol 50:443-446
40. Sehweikl H. Tuylor JA. Kitareewan S. Einko P. Nagornev D. Goldslein. JA (1993) Expression of CYP1AI and CYP1A2 genes in human liver. Pharmacogenelics 3:239-249
41. Sesardic D. Boobis AR. Edwards R.I. Davies DS (1998) A form of cytochrome P450 in man. orthologous to form D in the rat. catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26:363-372
42. Shields PG. Bowman EG. Harrington AM (1993) Polycyclic aromatic hydrocarbon DNA adducts in human lung and cancer susceptibility genes. Cancer Res 53:3486-3492
43. Shimada T. Yun CH. Yamazaki H. Gautier JC. Beaune PH. Guengerich FP (1992) Characterization of human lung microsomal cytochrome P450 1A1 and its role in oxidation of chemical carcinogens. Mol Pharmacol 41:856-864
44. Shimada T. Yamazaki H. Mimura M. Inui Y. Guengerieh FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. .1 Pharmacol Exp Ther 270:414-423
45. Shimada T. Haves CL. Yamazaki H. Amin S. Hecht SS. Giiengerieh FP. Sutler TR (1996) Activation of chemically diverse procarcinogens by human evtoehronie P-450 1B1. Cancer Res 56:2979-2984
46. Shimada T, Gillam FMJ. Sutler TR. Strickland PT. Guengrich FP. Yamazaki H (1997) Oxidation of xenobiolics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 25:617-622
47. Spivack SD; Fasco M.l. Walker VE. Kaminsky LS (1997) The molecular epidemiology of lung cancer. Crit Rev Foxicol 27:319-365
48. Sugimtira H. Haniada GS, Su/iki I, Iwase T, Kivokawa H. Kino I. Tsuganc S (1995) CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro. Brazil. Pharniacogenetics 5:S145-S148
49. Suiter TR, Tang YM, Hayes CL, Wo YYP. Jabs KW. Li X, Yin H. Cody CW. Greenlee WF ( 1994) Complete cDNA sequence of a human dioxin-inducible niRNA identifies a new gene subfamilv of cvlochrome P450 that maps to chromosome 2. .1 Biol Chem 269:13092-13099
50. Swanson HI. Bradlield CA (1993) 'fhe AH-receptor: genetics, structure and funelion. Pharniacogenetics 3:213-230
51. Tanaka F (I99X) In vivo age-related changes in hepatic drug-oxidi/ing capacity in humans. .1 Clin Pharm Ther 23:247-255
52. Tang BK. Zhou Y. Kadar D. Kalow W (1994) Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacosienetics 4:1 17 "l 24
53. Te Ire T. Ryberg D. Haugen A. Neben DW. Skaug V. Brogger A. Borresen AL (1991) Human CYP1A1 (cvlochrome P450) gene: lack of association between the .l/v/>/ restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharniacogenetics 1:20-25
54. Tyndale RF, Inaba T. Kalow W (1989) Kvidence in humans lor variant alloen/ymes of the nondelicient sparleine dcbrisoquine monooxygenase in vitro. Drug Metab Dispos 17:334 340
55. Welfare MR. Ailkm M. Bassendine MF. Daly AK ( 1999) Detailed modeling of calfeine metabolism and examination of the CYPIA2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics 9:367 375
56. Xu X, Kelsey KT. Wienche .IK. Wain JC. Christian! DC' (1996) Cvtochrome P450 CYP1AI MspI polymorphism and lung cancer susceptibility. Cancer Hpidemiol Biomarkers Prev 5:687-692
57. Yu MW. Chin YH". \'ang SY. Santella RM. C'hern HD. Liaw YF. Chen CM (1999) Cvlochrome P450 1AI genetic polymorphisms and risk of hepalocellular carcinoma among chronic hepatilis B carriers. Br .1 C'ancer ,XO:59,S 603
58. Zeeh .1. Fuchs L. Bergmann W. Antonin KH. Degel F. Bieck P. Platt D ( 1996) Influence of age. frailty and liver funelion on the pharmacokinelics of brofaromine. Eur J C'lin Pharmacol 49:3X7 391
59. 462: assessment of a role for therare allele in carcinogenesis. C'ancer Res 56:3925-3933